— Research note —
Sermorelin
Synthetic 29-amino-acid N-terminal fragment of native GHRH investigated as the minimal bioactive sequence for growth hormone-releasing activity.
Sermorelin is a synthetic 29-amino-acid peptide corresponding to the N-terminal 1-29 residues of native human growth hormone-releasing hormone (GHRH). Early structure-activity studies in the 1970s and 1980s established that the bioactivity of the 44-amino-acid endogenous hormone is largely retained in this N-terminal fragment, making sermorelin a useful surrogate for native GHRH in research and clinical contexts. The compound was developed by Salk Institute and Tulane investigators including Roger Guillemin (Nobel laureate, 1977) and Andrew Schally (Nobel laureate, 1977), and was the first GHRH preparation to receive regulatory approval, originally as a diagnostic agent for pituitary growth hormone reserve.
Unlike the modified analogs such as MOD-GRF or CJC-1295, sermorelin contains the native sequence without stabilizing substitutions, and consequently has a short plasma half-life of approximately 10 to 12 minutes due to rapid cleavage at the position 2 Ala-Asp bond by dipeptidyl peptidase-4 and other proteases. This short half-life is appropriate for diagnostic pulse-testing applications and for research protocols that require brief receptor stimulation.
In academic research, sermorelin has served as a benchmark GHRH agonist for studies of pituitary somatotroph function, the relative potency of newer GHRH analogs, and combination pharmacology with ghrelin receptor agonists. The compound has been compared with tesamorelin (an N-terminally modified GHRH analog with extended half-life), with MOD-GRF (the substituted 1-29 form), and with CJC-1295 with DAC (the long-acting albumin-conjugate form). Each of these molecules engages the same receptor with similar affinity but provides distinct pharmacokinetic profiles useful for different experimental questions.
The compound is supplied here for laboratory research use only and is not intended for human consumption. Its primary research applications include pituitary pharmacology, diagnostic GHRH testing in research models, and as a reference compound for comparative GHRH analog studies.
Mechanism
Sermorelin binds the GHRH receptor, a class B G-protein coupled receptor expressed on pituitary somatotrophs and at lower levels in extra-pituitary tissues including the hypothalamus and pancreas. Receptor engagement activates Gas, elevates intracellular cAMP, and stimulates protein kinase A-dependent transcription of the growth hormone gene as well as exocytosis of stored hormone from somatotroph secretory granules.
The native GHRH sequence is cleaved at the position 2 Ala-Asp bond by dipeptidyl peptidase-4, yielding the inactive GHRH (3-29) metabolite within minutes of administration. This rapid clearance limits sermorelin to short receptor-exposure durations, producing single growth hormone pulses with each administration. The pulse pattern recapitulates the dynamics of endogenous GHRH release more faithfully than long-acting analogs, an advantage in research contexts where pulsatile rather than sustained somatotroph activation is desired.
Research history
The identification of growth hormone-releasing hormone as a distinct hypothalamic factor was achieved in 1982 by the Guillemin, Rivier, and Vale groups at the Salk Institute, working with pancreatic tumor extracts that produced ectopic GHRH. The 44-amino-acid sequence was elucidated, and subsequent structure-activity work established that the N-terminal 29 residues retained essentially full biological activity.
Sermorelin (GHRH 1-29) was developed as a synthetic version of the bioactive minimum fragment and received regulatory approval in the United States in the late 1990s for diagnostic and limited therapeutic applications. The compound was used in pediatric and adult research populations to assess pituitary growth hormone reserve and was investigated in age-related decline of growth hormone secretion.
Academic research from the 1990s through the present has used sermorelin as a benchmark in combination studies with ghrelin receptor agonists, with results consistently showing synergistic growth hormone release when both receptor systems are engaged simultaneously. The compound continues to serve as a reference GHRH agonist in pharmacological characterizations of newer analogs and in mechanistic studies of somatotroph signaling.
References
- Guillemin R, et al. 1982. Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. Science. PMID: 6812220
- Rivier J, et al. 1982. Characterization of a growth hormone-releasing factor from a human pancreatic islet tumour. Nature. PMID: 6298637
- Thorner MO, et al. 1988. Acceleration of growth in two children treated with human growth hormone-releasing factor. N Engl J Med. PMID: 3093863
- Walker RF. 2006. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. PMID: 18046872
- Mayo KE, et al. 1995. Growth hormone-releasing hormone: synthesis and signaling. Recent Prog Horm Res. PMID: 7740160
- Frohman LA, Kineman RD. 2002. Growth hormone-releasing hormone and pituitary development, hyperplasia and tumorigenesis. Trends Endocrinol Metab.
Do you have any questions about Sermorelin?
Pick a path. The research assistant has the full literature context loaded.
Information presented in third-person scientific context. Research use only. Not medical advice; not for human consumption.